EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Insights into the Pharmacological Activity of the Imidazo−Pyrazole Scaffold

Andrea Spallarossa, Federica Rapetti, Maria Grazia Signorello, Camillo Rosano, Erika Iervasi, Marco Ponassi, Chiara Brullo iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Andrea Spallarossa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132, Genova, Italy. Hauptthemen laut MEDLINE: Tubulin, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Umberto Veronesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In previous studies, we synthesized different imidazo−pyrazoles 1 and 2 with interesting anticancer, anti‐angiogenic and anti‐inflammatory activities. To further extend the structure‐activity relationships of imidazo−pyrazole scaffold and to identify novel antiproliferative/anti‐inflammatory agents potentially active with multi‐target mechanisms, a library of compounds 3 – 5 has been designed and synthesized. The chemical modifications characterizing the novel derivatives include: i) decoration of the catechol ring with groups with different electronic, steric and lipophilic properties (compounds 3 ); ii) insertion of a methyl group on C‐6 of imidazo−pyrazole scaffold (compounds 4 ); iii) shift of the acylhydrazonic substituent from position 7 to 6 of the imidazo−pyrazole substructure (compounds 5 ). All synthesized compounds were tested against a panel of cancer and normal cell lines. Derivatives 3 a , 3 e , 4 c , 5 g and 5 h showed IC 50 values in the low micromolar range against selected tumor cell lines and proved to have antioxidant properties, being able to inhibit ROS production in human platelet. In silico calculation predicted favourable drug‐like and pharmacokinetic properties for the most promising compounds. Furthermore, molecular docking and molecular dynamic simulations suggested the ability of most active derivative 3 e to interact with colchicine binding site in the polymeric tubulin α/tubulin β/stathmin4 complex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TubulinAntineoplastic AgentsHumansMolecular Docking SimulationStructure-Activity RelationshipCell Line, TumorPyrazolesDrug Screening Assays, AntitumorMolecular StructureCell Proliferation

Stichwörter der Autor:innen

ROSanticancer activityimidazo−pyrazolesmedicinal chemistrymolecular docking

Substanzen

pyrazoleTubulinPyrazolesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132, Genova, Italy.
  • IRCCS Ospedale Policlinico San Martino Unit Proteomics and Mass Spectrometry, L.go. R. Benzi, 10, 16132, Genova, Italy.

ORCID-Profile: Chiara Brullo

Förderung

  • Fondazione Umberto Veronesi

Zitieren

APA

Spallarossa, A., Rapetti, F., Signorello, M. G., Rosano, C., Iervasi, E., Ponassi, M., & Brullo, C. (2023). Insights into the Pharmacological Activity of the Imidazo−Pyrazole Scaffold. ChemMedChem. https://doi.org/10.1002/cmdc.202300252

Vancouver

Spallarossa A, Rapetti F, Signorello MG, Rosano C, Iervasi E, Ponassi M, et al. Insights into the Pharmacological Activity of the Imidazo−Pyrazole Scaffold. ChemMedChem. 2023. doi:10.1002/cmdc.202300252

BibTeX
@article{Spallarossa2023,
  author = {Spallarossa, Andrea and Rapetti, Federica and Signorello, Maria Grazia and Rosano, Camillo and Iervasi, Erika and Ponassi, Marco and Brullo, Chiara},
  title = {Insights into the Pharmacological Activity of the Imidazo−Pyrazole Scaffold},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300252}
}
Kostenlos starten →